Natural Pharmaceutical Grade
Psychedelics for a New Generation
of Mental Health Therapeutics

Using botanicals Ibogaine and Psilocybin to offer
patients next generation drug treatment
Making psychedelics a natural part
of every doctor’s Rx pad
Botanically
sourced - not
synthesized
Proprietary,
proven
technology
Delivery using
microdosing for a
prolonged clinical
effect over time
No
psychoactive
effects

Transforming mental health

The world urgently needs a new way to treat mental health issues, and at Psyrx we believe psychedelics are a big part of the solution. Bringing over 20 years of experience in the pharmaceutical, medical device and cannabis industries, we set out to transform the growing psychedelics market. Psyrx is one of the few companies to offer GMP-standard naturally sourced (not synthesized) psychedelics based on high-quality botanic extracts from mushrooms (Psilocybin) and root bark (Ibogaine), produced using our agro-medical bioreactor platform.
We intend to use: these extracts to supply APIs to pharma companies or to improve current anti-depressant treatments through microdosing, with a convenient daily dose which does not cause a psychedelic experience and is non-disruptive to people’s way of life, limiting the side effects of current medications - helping transform mental health treatment outcomes.

Unleashing the therapeutic
potential of Ibogaine & Psilocybin

IBOGAINE

Ibogaine is the key psychoactive component of the Iboga plant. Ibogaine has been recognized as an anti-addiction drug that, following a single treatment, produces more successful results than traditional methods, while also reducing depression and anxiety.

Medical indications:

Treatment of addictions, Treatment of depression, fatigue and recovery from contagious diseases and High blood pressure.

Learn more
PSILOCYBIN

Sourced mainly from Magic mushrooms, Psilocybin has been shown to have a positive effect in treating depression, anxiety, and addiction, and has been suggested as a potential treatment for obesity, PTSD, and more.

Medical indications:

Major depressive disorder (MDD), Treatment-resistant depression, Anxiety, Addiction, Anorexia, Obesity, Cluster headaches, Alzheimer’s disease, PTSD, Personality disorders.

Learn more

Our applications

Providing API grade botanical molecules for psychiatric treatment & combining microdoses of Ibogaine to current anti-depressants treatment.
Supplying GMP standard APIs of Ibogaine
and Psilocybin to pharmaceutical and
biotechnology companies
Clinical advantage - Faster onset,
alleviates mood and limits side effects.
Safer with lower burden on patients and
reduced financial cost of treatment.
Adding microdoses of Ibogaine or
Psilocybin to current psychiatric drugs
Regulatory advantage - Accelerated
regulatory approval process

The natural pharmaceutical grade
psilocybin in 4 steps

1
Preparation of master
cell bank
First, we select the best psilocybin mushroom strains and prepare a master cell bank for a consistent manufacturing process, both currently and in the future
2
Mycelium isolation
For manufacturing a natural Psylocibin API batch, we grow specific mycelium from the master bank in a controlled bioreactor for 2 weeks
3
Extraction and isolation
(GMP process)
We extract the mushroom metabolites for a full spectrum extract followed by isolation of > 99% pure natural Psilocybin
4
Packaging and delivery
(GMP process)
We package and store our final product in a controlled environment, according to stability test validations and requirements until it is delivered to costumers

Using agro-medical methods
through our Bio-reactor platform

  • Controlled environment
  • Fully sterile processes
  • Fast growth
  • Consistent and reproducible high yield
  • Low-cost process

Leveraging existing know-how and technology

Licensed for research in
Psychedelic molecules by
the Israeli Ministry of Health
License agreement with
the Hebrew University of
Jerusalem (HUJI)
Fully IP protected
with exclusive
commercial rights

Our highly experienced team

Itay Hecht
C.E.O. and Co-Founder
Itay is an entrepreneur with vast experience in the private and public sector. He initiated the first public trade medical Cannabis company in Tel Aviv Stock Exchange. Itay served as the CEO of Hi-Pharma Ltd, a medical cannabis company for 2 years and 7 years as COO of Palgi Sharon - Israeli Municipal Water Corporation.
Asher Holzer Ph.D
Chairman and Co-founder
Asher has over 30 years' experience in management of both private and public corporations in the medical device and the biotech industry. Asher founded several successful bio-tech companies, including InspireMD (NYSE MKT: NSPR) and UroGen Pharma (NASDAQ: URGN). He was part of the management team of Biosense (acquired by Johnson & Johnson).
Kobi Buxdorf Ph.D
CTO and Co- founder
Kobi is an entrepreneur and founder of CANNADORF LTD, bringing over 10 years of academic and industrial research and management experience in multidisciplinary areas in the field of microbiology, molecular biology, plant sciences, diagnostics, and medical devices. He also possesses an extensive background in regulation and business development.
Noam Barnea-Ygael Ph.D
Research Officer
Noam has over 15 years of academic experience in the field of neuroscience and over 10 years of industrial experience at a medical device company that targets psychiatric conditions (BrainsWay Ltd.).
Yair Alerganti, B.Sc
COO
20 years of experience of regulatory affairs and clinical studies in the field of pharmaceuticals, medical devices, food supplements and cosmetics. Prior to PsyRx, Yair was Co-Founder and Chief of Regulatory Affairs at Q2Pharma, established TRS Ltd (a CRO), served as VP Clinical development at HealOr Ltd, mmanaged Israeli Clinical Studies at Novartis, and headed the clinical operation at NanoPass.

Advisory Board

Jeremy Weate Ph.D
Scientific Advisor
Maggie Levy PhD
Head of Agricultural Research

The next generation
of psychedelics is
already here

If you want to be a part of it,
we’d love to hear from you
Get In Touch





    Skip to content